NASDAQ:PTGX - Protagonist Therapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$6.29 -0.05 (-0.79 %)
(As of 05/23/2018 06:56 AM ET)
Previous Close$6.34
Today's Range$6.05 - $6.47
52-Week Range$5.50 - $23.97
Volume231,225 shs
Average Volume221,420 shs
Market Capitalization$134.43 million
P/E Ratio-3.01
Dividend YieldN/A
Beta3.54

About Protagonist Therapeutics (NASDAQ:PTGX)

Protagonist Therapeutics logoProtagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a peptide technology platform focused on discovering and developing new chemical entities (NECs) to address significant unmet medical needs. The Company's product pipeline includes PTG-100, PTG-200 and PTG-300. Its primary focus is on developing oral peptide drugs that target biological pathways also targeted by marketed injectable antibody drugs. PTG-100 is an oral, alpha-4-beta-7 (a4b7) integrin-specific antagonist peptide product candidate, which has completed a Phase I clinical trial in normal healthy volunteers (NHVs). PTG-100 is being developed for treatment of moderate-to-severe ulcerative colitis (UC). PTG-200 is an oral Interleukin-23 receptor (IL-23R) antagonist being developed for moderate-to-severe Crohn's disease (CD). PTG-200 is in investigational new drug (IND) enabling studies. PTG-300 is an injectable hepcidin mimetic for treatment of iron overload related rare diseases.

Receive PTGX News and Ratings via Email

Sign-up to receive the latest news and ratings for PTGX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:PTGX
CUSIPN/A
Phone510-474-0170

Debt

Debt-to-Equity RatioN/A
Current Ratio4.19
Quick Ratio4.19

Price-To-Earnings

Trailing P/E Ratio-3.01
Forward P/E Ratio-6.42
P/E GrowthN/A

Sales & Book Value

Annual Sales$20.06 million
Price / Sales6.65
Cash FlowN/A
Price / CashN/A
Book Value$5.41 per share
Price / Book1.16

Profitability

EPS (Most Recent Fiscal Year)($2.09)
Net Income$-36,950,000.00
Net MarginsN/A
Return on Equity-34.47%
Return on Assets-24.72%

Miscellaneous

Employees55
Outstanding Shares21,200,000

Protagonist Therapeutics (NASDAQ:PTGX) Frequently Asked Questions

What is Protagonist Therapeutics' stock symbol?

Protagonist Therapeutics trades on the NASDAQ under the ticker symbol "PTGX."

How were Protagonist Therapeutics' earnings last quarter?

Protagonist Therapeutics Inc (NASDAQ:PTGX) issued its earnings results on Wednesday, May, 9th. The company reported ($0.36) earnings per share for the quarter, missing the consensus estimate of ($0.29) by $0.07. The company earned $10.78 million during the quarter, compared to the consensus estimate of $10.70 million. View Protagonist Therapeutics' Earnings History.

When is Protagonist Therapeutics' next earnings date?

Protagonist Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, August, 6th 2018. View Earnings Estimates for Protagonist Therapeutics.

What price target have analysts set for PTGX?

3 brokerages have issued 1-year price targets for Protagonist Therapeutics' shares. Their predictions range from $13.00 to $36.00. On average, they expect Protagonist Therapeutics' share price to reach $27.00 in the next twelve months. View Analyst Ratings for Protagonist Therapeutics.

Who are some of Protagonist Therapeutics' key competitors?

Who are Protagonist Therapeutics' key executives?

Protagonist Therapeutics' management team includes the folowing people:
  • Harold E. Selick Ph.D., Independent Chairman of the Board (Age 62)
  • Dinesh V. Patel Ph.D., President, Chief Executive Officer, Director (Age 59)
  • Thomas P. O'Neil, Chief Financial Officer (Age 51)
  • William A. Hodder, Senior Vice President - Corporate Development (Age 52)
  • David Y. Liu Ph.D., Chief Scientific Officer, Head of Research & Development (Age 66)
  • Ashok Bhandari Ph.D., Vice President - Chemistry (Age 52)
  • Larry Mattheakis Ph.D., Vice President - Biology (Age 59)
  • Mark Smythe Ph.D., Vice President -Technology & Alliances (Age 51)
  • Thamil Annamalai, Senior Director - Pre-clinical Development (Age 56)
  • Richard S Shames M.D., Chief Medical Officer (Age 57)

When did Protagonist Therapeutics IPO?

(PTGX) raised $70 million in an IPO on Thursday, August 11th 2016. The company issued 5,800,000 shares at a price of $11.00-$13.00 per share. Leerink Partners, Barclays and BMO Capital Markets acted as the underwriters for the IPO.

Has Protagonist Therapeutics been receiving favorable news coverage?

Media stories about PTGX stock have trended somewhat positive this week, according to Accern. The research group rates the sentiment of news coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Protagonist Therapeutics earned a media sentiment score of 0.15 on Accern's scale. They also gave media stories about the company an impact score of 47.31 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.

Who are Protagonist Therapeutics' major shareholders?

Protagonist Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Farallon Capital Management LLC (4.78%), BlackRock Inc. (3.24%), BVF Inc. IL (1.92%), Millennium Management LLC (1.51%), American Century Companies Inc. (0.67%) and Spark Investment Management LLC (0.39%). Company insiders that own Protagonist Therapeutics stock include Armen Shanafelt, Bryan Giraudo, David Y Liu, Dinesh V Ph D Patel, Richard S Shames, Thomas P O'neil and X LP Canaan. View Institutional Ownership Trends for Protagonist Therapeutics.

Which institutional investors are buying Protagonist Therapeutics stock?

PTGX stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., American Century Companies Inc., Millennium Management LLC, Farallon Capital Management LLC, BVF Inc. IL, Spark Investment Management LLC, Citadel Advisors LLC and Federated Investors Inc. PA. Company insiders that have bought Protagonist Therapeutics stock in the last two years include Armen Shanafelt and Bryan Giraudo. View Insider Buying and Selling for Protagonist Therapeutics.

How do I buy shares of Protagonist Therapeutics?

Shares of PTGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Protagonist Therapeutics' stock price today?

One share of PTGX stock can currently be purchased for approximately $6.29.

How big of a company is Protagonist Therapeutics?

Protagonist Therapeutics has a market capitalization of $134.43 million and generates $20.06 million in revenue each year. The company earns $-36,950,000.00 in net income (profit) each year or ($2.09) on an earnings per share basis. Protagonist Therapeutics employs 55 workers across the globe.

How can I contact Protagonist Therapeutics?

Protagonist Therapeutics' mailing address is 7707 GATEWAY BOULEVARD SUITE 140, NEWARK CA, 94560-1160. The company can be reached via phone at 510-474-0170 or via email at [email protected]


MarketBeat Community Rating for Protagonist Therapeutics (PTGX)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  96 (Vote Outperform)
Underperform Votes:  134 (Vote Underperform)
Total Votes:  230
MarketBeat's community ratings are surveys of what our community members think about Protagonist Therapeutics and other stocks. Vote "Outperform" if you believe PTGX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PTGX will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Protagonist Therapeutics (NASDAQ:PTGX) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
3 Wall Street analysts have issued ratings and price targets for Protagonist Therapeutics in the last 12 months. Their average twelve-month price target is $27.00, suggesting that the stock has a possible upside of 329.25%. The high price target for PTGX is $36.00 and the low price target for PTGX is $13.00. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.672.673.003.00
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $27.00$27.00$37.00$39.50
Price Target Upside: 329.25% upside208.57% upside92.41% upside168.52% upside

Protagonist Therapeutics (NASDAQ:PTGX) Consensus Price Target History

Price Target History for Protagonist Therapeutics (NASDAQ:PTGX)

Protagonist Therapeutics (NASDAQ:PTGX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/26/2018BMO Capital MarketsReiterated RatingBuy ➝ Outperform$42.00 ➝ $13.00LowView Rating Details
3/26/2018Stifel NicolausDowngradeBuy ➝ HoldMediumView Rating Details
7/21/2017BTIG ResearchInitiated CoverageBuy ➝ Buy$36.00MediumView Rating Details
9/6/2016Leerink SwannInitiated CoverageOutperform$17.00N/AView Rating Details
9/6/2016BarclaysInitiated CoverageOverweight$18.00N/AView Rating Details
(Data available from 5/23/2016 forward)

Earnings

Protagonist Therapeutics (NASDAQ:PTGX) Earnings History and Estimates Chart

Earnings by Quarter for Protagonist Therapeutics (NASDAQ:PTGX)

Protagonist Therapeutics (NASDAQ:PTGX) Earnings Estimates

2018 EPS Consensus Estimate: ($1.03)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.13)($0.13)($0.13)
Q2 20181($0.51)($0.51)($0.51)
Q3 20181($0.60)($0.60)($0.60)
Q4 20181$0.21$0.21$0.21

Protagonist Therapeutics (NASDAQ PTGX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/6/2018($0.25)N/AView Earnings Details
5/9/2018Q1 2018($0.29)($0.36)$10.70 million$10.78 millionViewN/AView Earnings Details
3/7/2018Q4 2017($0.3420)($0.15)$8.75 million$11.28 millionViewN/AView Earnings Details
11/6/2017Q3 2017($0.6920)($0.29)$8.78 millionViewN/AView Earnings Details
8/8/2017Q2 2017($0.1870)($0.89)ViewN/AView Earnings Details
5/10/2017Q1 2017($0.61)($0.84)ViewN/AView Earnings Details
3/7/2017Q4 2016($0.4930)($0.67)ViewN/AView Earnings Details
11/14/2016Q3 2016($0.58)($0.87)ViewN/AView Earnings Details
9/15/2016Q2 2016($1.07)($19.07)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Protagonist Therapeutics (NASDAQ:PTGX) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Protagonist Therapeutics (NASDAQ PTGX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 13.80%
Institutional Ownership Percentage: 61.50%
Insider Trading History for Protagonist Therapeutics (NASDAQ:PTGX)
Insider Trading History for Protagonist Therapeutics (NASDAQ:PTGX)

Protagonist Therapeutics (NASDAQ PTGX) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/16/2018Bryan GiraudoDirectorBuy10,000$6.46$64,600.0010,000View SEC Filing  
5/16/2018X L.P. CanaanMajor ShareholderSell164,747$6.42$1,057,675.74View SEC Filing  
5/14/2018X L.P. CanaanMajor ShareholderSell77,591$6.37$494,254.67View SEC Filing  
3/22/2018X L.P. CanaanMajor ShareholderSell39,518$20.61$814,465.98View SEC Filing  
3/19/2018X L.P. CanaanMajor ShareholderSell20,365$20.55$418,500.75View SEC Filing  
3/15/2018X L.P. CanaanMajor ShareholderSell13,155$20.66$271,782.30View SEC Filing  
3/13/2018X L.P. CanaanMajor ShareholderSell1,204$20.84$25,091.36View SEC Filing  
3/12/2018David Y LiuInsiderSell3,500$21.29$74,515.00View SEC Filing  
3/2/2018David Y LiuInsiderSell875$20.00$17,500.0013,322View SEC Filing  
1/16/2018David Y LiuInsiderSell875$20.00$17,500.004,697View SEC Filing  
12/22/2017Richard S ShamesInsiderSell3,529$20.50$72,344.503,529View SEC Filing  
12/20/2017Dinesh V Ph D PatelInsiderSell1,790$19.55$34,994.50192,227View SEC Filing  
12/18/2017David Y LiuInsiderSell875$20.00$17,500.004,697View SEC Filing  
12/18/2017Thomas P O'neilCFOSell8,000$20.00$160,000.004,000View SEC Filing  
11/30/2017David Y LiuInsiderSell875$20.00$17,500.004,697View SEC Filing  
11/13/2017David Y. LiuInsiderSell7,000$16.97$118,790.00View SEC Filing  
10/5/2017Richard S ShamesInsiderSell2,017$19.00$38,323.00View SEC Filing  
9/12/2017Richard S. ShamesInsiderSell3,687$14.31$52,760.97View SEC Filing  
8/29/2017Richard S. ShamesInsiderSell1,512$17.00$25,704.00View SEC Filing  
8/28/2017David Y LiuInsiderSell3,500$15.00$52,500.005,500View SEC Filing  
7/10/2017David Y. LiuInsiderSell3,500$12.68$44,380.00View SEC Filing  
8/16/2016Armen ShanafeltDirectorBuy583,333$12.00$6,999,996.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Protagonist Therapeutics (NASDAQ PTGX) News Headlines

Source:
DateHeadline
Bryan Giraudo Acquires 10,000 Shares of Protagonist Therapeutics Inc (PTGX) StockBryan Giraudo Acquires 10,000 Shares of Protagonist Therapeutics Inc (PTGX) Stock
www.americanbankingnews.com - May 17 at 8:33 PM
Protagonist Therapeutics Announces Two Oral Presentations Accepted for 23rd Congress of the European Hematology AssociationProtagonist Therapeutics Announces Two Oral Presentations Accepted for 23rd Congress of the European Hematology Association
finance.yahoo.com - May 17 at 4:40 PM
Insider Selling: Protagonist Therapeutics Inc (PTGX) Major Shareholder Sells 77,591 Shares of StockInsider Selling: Protagonist Therapeutics Inc (PTGX) Major Shareholder Sells 77,591 Shares of Stock
www.americanbankingnews.com - May 16 at 7:52 PM
Insider Selling: Protagonist Therapeutics Inc (PTGX) Major Shareholder Sells 164,747 Shares of StockInsider Selling: Protagonist Therapeutics Inc (PTGX) Major Shareholder Sells 164,747 Shares of Stock
www.americanbankingnews.com - May 16 at 7:32 PM
Protagonist Therapeutics Appoints Bryan Giraudo to Board of DirectorsProtagonist Therapeutics Appoints Bryan Giraudo to Board of Directors
finance.yahoo.com - May 16 at 9:49 AM
Protagonist Therapeutics Inc (PTGX) Expected to Announce Quarterly Sales of $9.30 MillionProtagonist Therapeutics Inc (PTGX) Expected to Announce Quarterly Sales of $9.30 Million
www.americanbankingnews.com - May 14 at 4:59 AM
Leerink Swann Comments on Protagonist Therapeutics Incs Q2 2018 Earnings (PTGX)Leerink Swann Comments on Protagonist Therapeutics Inc's Q2 2018 Earnings (PTGX)
www.americanbankingnews.com - May 14 at 1:56 AM
Zacks: Brokerages Anticipate Protagonist Therapeutics Inc (PTGX) to Post -$0.18 Earnings Per ShareZacks: Brokerages Anticipate Protagonist Therapeutics Inc (PTGX) to Post -$0.18 Earnings Per Share
www.americanbankingnews.com - May 12 at 3:18 AM
Zacks Investment Research Lowers Protagonist Therapeutics (PTGX) to HoldZacks Investment Research Lowers Protagonist Therapeutics (PTGX) to Hold
www.americanbankingnews.com - May 11 at 12:49 PM
Q4 2018 EPS Estimates for Protagonist Therapeutics Inc Decreased by Analyst (PTGX)Q4 2018 EPS Estimates for Protagonist Therapeutics Inc Decreased by Analyst (PTGX)
www.americanbankingnews.com - May 11 at 10:52 AM
Protagonist Therapeutics (PTGX) Posts Quarterly  Earnings Results, Misses Expectations By $0.07 EPSProtagonist Therapeutics (PTGX) Posts Quarterly Earnings Results, Misses Expectations By $0.07 EPS
www.americanbankingnews.com - May 10 at 8:29 PM
Protagonist Therapeutics: 1Q Earnings SnapshotProtagonist Therapeutics: 1Q Earnings Snapshot
finance.yahoo.com - May 10 at 9:27 AM
Protagonist Therapeutics Reports First Quarter 2018 Financial ResultsProtagonist Therapeutics Reports First Quarter 2018 Financial Results
finance.yahoo.com - May 9 at 4:43 PM
Protagonist Therapeutics Inc (PTGX) Given Consensus Rating of "Hold" by BrokeragesProtagonist Therapeutics Inc (PTGX) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - May 9 at 3:28 AM
Sarepta (SRPT) Q1 Loss Narrows, Exondys 51 Sales ImpressSarepta (SRPT) Q1 Loss Narrows, Exondys 51 Sales Impress
finance.yahoo.com - May 4 at 4:46 PM
Protagonist Therapeutics Announces Oral Presentation Accepted for Digestive Diseases Week ConferenceProtagonist Therapeutics Announces Oral Presentation Accepted for Digestive Diseases Week Conference
finance.yahoo.com - May 3 at 9:08 AM
Protagonist Therapeutics (PTGX) Scheduled to Post Earnings on TuesdayProtagonist Therapeutics (PTGX) Scheduled to Post Earnings on Tuesday
www.americanbankingnews.com - May 1 at 7:26 AM
Protagonist Therapeutics Inc (PTGX) Expected to Post Quarterly Sales of $10.70 MillionProtagonist Therapeutics Inc (PTGX) Expected to Post Quarterly Sales of $10.70 Million
www.americanbankingnews.com - April 26 at 2:36 AM
Zacks: Brokerages Expect Protagonist Therapeutics Inc (PTGX) Will Post Earnings of -$0.24 Per ShareZacks: Brokerages Expect Protagonist Therapeutics Inc (PTGX) Will Post Earnings of -$0.24 Per Share
www.americanbankingnews.com - April 24 at 3:10 PM
Protagonist Therapeutics (PTGX) Stock Rating Upgraded by Zacks Investment ResearchProtagonist Therapeutics (PTGX) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - April 14 at 12:19 PM
Protagonist Therapeutics Inc (PTGX) Given Average Rating of "Hold" by AnalystsProtagonist Therapeutics Inc (PTGX) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - April 14 at 3:31 AM
Short Interest in Protagonist Therapeutics Inc (PTGX) Decreases By 62.3%Short Interest in Protagonist Therapeutics Inc (PTGX) Decreases By 62.3%
www.americanbankingnews.com - April 14 at 2:29 AM
Protagonist Therapeutics (PTGX) Enters Oversold TerritoryProtagonist Therapeutics (PTGX) Enters Oversold Territory
finance.yahoo.com - April 13 at 9:30 AM
-$0.24 Earnings Per Share Expected for Protagonist Therapeutics Inc (PTGX) This Quarter-$0.24 Earnings Per Share Expected for Protagonist Therapeutics Inc (PTGX) This Quarter
www.americanbankingnews.com - April 7 at 5:20 PM
Protagonist Therapeutics (PTGX) Downgraded by BidaskClubProtagonist Therapeutics (PTGX) Downgraded by BidaskClub
www.americanbankingnews.com - March 30 at 2:19 PM
3 Things In Biotech, March 29: Bristol And Protagonist Opposite Day In The Colon3 Things In Biotech, March 29: Bristol And Protagonist Opposite Day In The Colon
seekingalpha.com - March 30 at 9:17 AM
Biotech Stock Roundup: PTGX Down, VRNA Up, AMGNs Repatha Gets Positive OpinionBiotech Stock Roundup: PTGX Down, VRNA Up, AMGN's Repatha Gets Positive Opinion
www.zacks.com - March 28 at 4:38 PM
Protagonist Therapeutics Stalls Ulcerative Colitis StudyProtagonist Therapeutics Stalls Ulcerative Colitis Study
finance.yahoo.com - March 27 at 4:46 PM
BMO Capital Markets Reiterates "Buy" Rating for Protagonist Therapeutics (PTGX)BMO Capital Markets Reiterates "Buy" Rating for Protagonist Therapeutics (PTGX)
www.americanbankingnews.com - March 26 at 9:18 PM
Protagonist Therapeutics stock plunges after colitis treatment trial deemed futileProtagonist Therapeutics' stock plunges after colitis treatment trial deemed 'futile'
www.marketwatch.com - March 26 at 4:49 PM
Protagonist Therapeutics (PTGX) Discontinues Phase 2b PROPEL Trial of PTG-100 for Treatment of UC following Interim AnalysisProtagonist Therapeutics (PTGX) Discontinues Phase 2b PROPEL Trial of PTG-100 for Treatment of UC following Interim Analysis
www.streetinsider.com - March 26 at 4:49 PM
Why KB Home, Longfin, and Protagonist Therapeutics Slumped TodayWhy KB Home, Longfin, and Protagonist Therapeutics Slumped Today
finance.yahoo.com - March 26 at 4:49 PM
Why Protagonist Therapeutics, Inc. Is Imploding TodayWhy Protagonist Therapeutics, Inc. Is Imploding Today
finance.yahoo.com - March 26 at 4:49 PM
Protagonist Therapeutics (PTGX) Rating Lowered to Hold at Stifel NicolausProtagonist Therapeutics (PTGX) Rating Lowered to Hold at Stifel Nicolaus
www.americanbankingnews.com - March 26 at 4:18 PM
Protagonist Therapeutics Discontinues Phase 2b PROPEL Trial of PTG-100 for the Treatment of Ulcerative Colitis following Interim AnalysisProtagonist Therapeutics Discontinues Phase 2b PROPEL Trial of PTG-100 for the Treatment of Ulcerative Colitis following Interim Analysis
finance.yahoo.com - March 26 at 10:08 AM
Protagonist Therapeutics (PTGX) Rating Lowered to Sell at BidaskClubProtagonist Therapeutics (PTGX) Rating Lowered to Sell at BidaskClub
www.americanbankingnews.com - March 23 at 7:56 PM
Insider Selling: Protagonist Therapeutics Inc (PTGX) Major Shareholder Sells 39,518 Shares of StockInsider Selling: Protagonist Therapeutics Inc (PTGX) Major Shareholder Sells 39,518 Shares of Stock
www.americanbankingnews.com - March 22 at 7:14 PM
-$0.24 EPS Expected for Protagonist Therapeutics Inc (PTGX) This Quarter-$0.24 EPS Expected for Protagonist Therapeutics Inc (PTGX) This Quarter
www.americanbankingnews.com - March 21 at 5:14 PM
Protagonist Therapeutics Inc (PTGX) Receives Consensus Recommendation of "Buy" from AnalystsProtagonist Therapeutics Inc (PTGX) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - March 20 at 3:34 AM
Insider Selling: Protagonist Therapeutics Inc (PTGX) Major Shareholder Sells 20,365 Shares of StockInsider Selling: Protagonist Therapeutics Inc (PTGX) Major Shareholder Sells 20,365 Shares of Stock
www.americanbankingnews.com - March 19 at 8:20 PM
Protagonist Therapeutics (PTGX) Lifted to Buy at Zacks Investment ResearchProtagonist Therapeutics (PTGX) Lifted to Buy at Zacks Investment Research
www.americanbankingnews.com - March 18 at 11:14 AM
Protagonist Therapeutics to Participate in the 28th Annual Oppenheimer Healthcare ConferenceProtagonist Therapeutics to Participate in the 28th Annual Oppenheimer Healthcare Conference
finance.yahoo.com - March 17 at 10:12 AM
Insider Selling: Protagonist Therapeutics Inc (PTGX) Major Shareholder Sells 13,155 Shares of StockInsider Selling: Protagonist Therapeutics Inc (PTGX) Major Shareholder Sells 13,155 Shares of Stock
www.americanbankingnews.com - March 15 at 8:42 PM
Protagonist Therapeutics Inc (PTGX) Major Shareholder X L.P. Canaan Sells 1,204 SharesProtagonist Therapeutics Inc (PTGX) Major Shareholder X L.P. Canaan Sells 1,204 Shares
www.americanbankingnews.com - March 15 at 8:28 PM
David Y. Liu Sells 3,500 Shares of Protagonist Therapeutics Inc (PTGX) StockDavid Y. Liu Sells 3,500 Shares of Protagonist Therapeutics Inc (PTGX) Stock
www.americanbankingnews.com - March 13 at 8:32 PM
Protagonist Therapeutics Inc (PTGX) Expected to Post Q1 2018 Earnings of ($0.13) Per ShareProtagonist Therapeutics Inc (PTGX) Expected to Post Q1 2018 Earnings of ($0.13) Per Share
www.americanbankingnews.com - March 12 at 1:52 AM
Protagonist Therapeutics (PTGX) Price Target Cut to $42.00Protagonist Therapeutics (PTGX) Price Target Cut to $42.00
www.americanbankingnews.com - March 8 at 7:13 PM
Protagonist Therapeutics (PTGX) Posts Quarterly  Earnings Results, Beats Expectations By $0.19 EPSProtagonist Therapeutics (PTGX) Posts Quarterly Earnings Results, Beats Expectations By $0.19 EPS
www.americanbankingnews.com - March 8 at 10:29 AM
Protagonist Therapeutics Reports Fourth Quarter and Year-End 2017 Financial ResultsProtagonist Therapeutics Reports Fourth Quarter and Year-End 2017 Financial Results
finance.yahoo.com - March 7 at 4:43 PM
Protagonist Therapeutics, Inc. to Host Earnings CallProtagonist Therapeutics, Inc. to Host Earnings Call
finance.yahoo.com - March 7 at 4:43 PM

SEC Filings

Protagonist Therapeutics (NASDAQ:PTGX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Protagonist Therapeutics (NASDAQ:PTGX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Protagonist Therapeutics (NASDAQ PTGX) Stock Chart for Wednesday, May, 23, 2018

Loading chart…

This page was last updated on 5/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.